ClinicalTrials.gov
ClinicalTrials.gov Menu

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00096304
Recruitment Status : Terminated (Low accrual)
First Posted : November 9, 2004
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
Medical University of South Carolina

November 9, 2004
November 9, 2004
April 10, 2018
June 8, 2004
September 6, 2006   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00096304 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer

RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.

Not Provided
Interventional
Phase 1
Primary Purpose: Treatment
Prostate Cancer
  • Drug: docetaxel
  • Drug: epirubicin hydrochloride
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
36
Not Provided
November 30, 2007
September 6, 2006   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the prostate
  • Meets 1 of the following criteria:

    • Measurable disease with any prostate-specific antigen (PSA) value

      • Unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
      • Histologic confirmation required if measurable disease is confined to a solitary lesion
    • Non-measurable disease with PSA ≥ 5 ng/mL*

      • The following are considered non-measurable disease:

        • Bone lesions
        • Pleural or pericardial effusion
        • Ascites
        • CNS lesions
        • Leptomeningeal disease
        • Irradiated lesions unless disease progression was documented after prior radiotherapy NOTE: *Patients with PSA ≥ 5 ng/mL only are not eligible
  • Progressive systemic disease despite ≥ 1 prior standard endocrine therapy with orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonist, or diethylstilbestrol, as indicated by 1 of the following criteria:

    • Objective evidence of increase > 20% in the sum of the longest diameters of target lesions from the time of maximal regression OR the appearance of 1 or more new lesions
    • One or more new lesions on bone scan secondary to prostate cancer AND PSA ≥ 5 ng/mL
    • Elevated PSA (≥ 5 ng/mL) with 2 consecutive increases from baseline (taken ≥ 1 week apart)
  • Serum testosterone ≤ 50 ng/dL for patients without bilateral orchiectomy

    • Patients who have not had a bilateral orchiectomy should continue therapy with primary testicular androgen suppression (e.g., LHRH analogues)

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • Granulocyte count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3

Hepatic

  • Meets 1 of the following criteria:

    • AST or ALT normal AND alkaline phosphatase ≤ 5 times upper limit of normal (ULN)
    • AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN
    • AST or ALT ≤ 5 times ULN AND alkaline phosphatase normal
  • Bilirubin normal

Renal

  • Creatinine ≤ 1.5 times ULN

Cardiovascular

  • No uncontrolled high blood pressure
  • No unstable angina
  • No symptomatic congestive heart failure
  • No myocardial infarction within the past 6 months
  • No serious uncontrolled cardiac arrhythmia
  • No New York Heart Association class III or IV heart disease

Other

  • Fertile patients must use effective contraception during and for at least 3 months after study participation
  • No peripheral neuropathy ≥ grade 2
  • No prior severe hypersensitivity reaction to docetaxel or other drug formulated with polysorbate 80

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

Chemotherapy

  • No prior chemotherapy, including estramustine or suramin for prostate cancer
  • No other concurrent chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 4 weeks since prior antiandrogen therapy
  • No concurrent hormonal therapy except steroids for adrenal insufficiency, hormones for non-disease-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic

Radiotherapy

  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy
  • At least 8 weeks since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium
  • No concurrent palliative radiotherapy

Surgery

  • See Disease Characteristics
  • At least 4 weeks since prior surgery and recovered
Sexes Eligible for Study: Male
18 Years to 120 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00096304
MUSC-100781
CDR0000378045 ( Registry Identifier: PDQ (Physician Data Query) )
MUSC-HR-11325
AVENTIS-MUSC-100781
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Not Provided
Medical University of South Carolina
Medical University of South Carolina
Not Provided
Principal Investigator: Andrew S. Kraft, MD Medical University of South Carolina
Study Chair: Gustavo Leone Medical University of South Carolina, Hollings Cancer Center
Medical University of South Carolina
April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP